Latest News of VCYT
Here's Why Baron Discovery Fund Increased its Holdings in Veracyte (VCYT)
Baron Funds released its Q2 2024 investor letter for the Baron Discovery Fund, highlighting Veracyte, Inc. (NASDAQ:VCYT). The stock showed strong performance with a 38.95% one-month return and a 27% i...
Insider Sale: Director Jens Holstein Sells 5,000 Shares of Veracyte Inc (VCYT)
Director Jens Holstein sold 5,000 shares of Veracyte Inc on July 16, 2024, reducing his holdings to 32,878 shares. Veracyte specializes in genomic diagnostics, providing actionable results for patient...
Market Sentiment Around Loss-Making Veracyte, Inc. (NASDAQ:VCYT)
Veracyte, Inc. is a diagnostics company aiming to reach profitability soon. Analysts predict the company will break even in 2024 and turn a profit in 2025, expecting a high growth rate....